From: Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes
Parameters | 0 No screening | 1 EMR symptoms | 2 EMR symptoms Physical exam | 3 EMR symptoms Physical exam NTproBNP | 4 EMR symptoms Physical exam NTproBNP ECG | 5 Echo cardio- graphy | Distribution | Source |
---|---|---|---|---|---|---|---|---|
Sensitivitya | ||||||||
 NYHA 1 | 0.000 | 0.250 | 0.250 | 0.250 | 0.500 | 1.000 | Beta | Cohort [5] |
 NYHA 2 | 0.000 | 0.853 | 0.853 | 0.879 | 0.862 | 1.000 | Beta | Cohort [5] |
 NYHA 3 | 0.000 | 0.923 | 0.949 | 0.897 | 0.897 | 1.000 | Beta | Cohort [5] |
 NYHA 4 | 0.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | Beta | Cohort [5] |
Specificity | 1.000 | 0.610 | 0.617 | 0.652 | 0.676 | 1.000 | Beta | Cohort [5] |
Screening | ||||||||
 GP | €0.00b | €6.39 | €15.17 | €36.67 | €61.77 | €0.00c | Gamma | |
 Echocardiography | €169.38 | €169.38 | €169.38 | €169.38 | €169.38 | €169.38 | Gamma | |
 ECG stress test | €94.75 | €94.75 | €94.75 | €94.75 | €94.75 | €94.75 | Gamma |